India to join hands with WHO for developing coronavirus drugs: Govt

At a press briefing on coronavirus at 4 pm, Health Ministry Joint Secretary Lav Agarwal said 75 new cases of coronavirus and four deaths have been reported in the last 24 hours.

lockdown, coronavirus
A view of Ghazipur vegetable market bustling with activity during a nationwide lockdown in the wake of coronavirus pandemic, in New Delhi
Press Trust of India
2 min read Last Updated : Mar 27 2020 | 8:09 PM IST

India is soon likely to participate in the WHO's "solidarity trial" for developing potential drugs for COVID-19, officials said on Friday.

At a press briefing on coronavirus at 4 pm, Health Ministry Joint Secretary Lav Agarwal said 75 new cases of coronavirus and four deaths have been reported in the last 24 hours.

"We are soon likely to participate in the WHO solidarity trial for developing potential drugs for COVID-19. Earlier we did not do it because our numbers were small and our contribution would have looked minuscule," Raman R Gangakhedkar, Head of Epidemiology and Communicable diseases at ICMR, said.

Agarwal said that a PSU has been ordered to provide 10,000 ventilators while Bharat Electronics Limited (BEL) has been requested to purchase 30,000 additional ventilators in one-two months amidst a shortage of the machines in the country.

Punya Salila Srivastava, Joint Secretary in the Ministry of Home Affairs (MHA), said that states and union territories (UTs) have been requested to make arrangements for food, water and sanitation for migrant labourers. Hotels and rented accommodation should stay open and functional.

She, however, ruled out any plan to ferry stranded migrants from across cities or states, saying that the whole idea of a lockdown was to ensure no movement of people from their present places.

Agarwal also said that keeping in mind that hospital OPDs are being shut, the government has issued national telemedicine guidelines.

"This facilitates the process wherein doctors sitting at their homes can provide services to the patients. We urge and request citizens to take advantage of it and doctors to utilise this," he said.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusWorld Health Organisation

Next Story